🇺🇸 FDA

Company profile · Sponsor

Swedish

Swedish Orphan Biovitrum International AB

E2F8E99 · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

Swedish (E2F8E99) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E2F8E99
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. NI-501; emapalumab, NI-501; emapalumab

    Swedish

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  2. An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes

    Swedish

    Nicotine use

    phase 1 other active

    1 trial

Frequently asked questions

What is Swedish?

Swedish (E2F8E99) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Swedish sponsor?

We track 2 ClinicalTrials.gov-linked programs for Swedish, including NI-501; emapalumab, NI-501; emapalumab and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Swedish company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.